Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2001 1
2004 1
2005 1
2006 2
2008 2
2009 1
2010 4
2012 1
2014 1
2017 5
2018 7
2019 16
2020 33
2021 44
2022 36
2023 33
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for juno he
Search for Junou He instead (1 results)
Integrated analysis of multimodal single-cell data.
Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, Lee MJ, Wilk AJ, Darby C, Zager M, Hoffman P, Stoeckius M, Papalexi E, Mimitou EP, Jain J, Srivastava A, Stuart T, Fleming LM, Yeung B, Rogers AJ, McElrath JM, Blish CA, Gottardo R, Smibert P, Satija R. Hao Y, et al. Cell. 2021 Jun 24;184(13):3573-3587.e29. doi: 10.1016/j.cell.2021.04.048. Epub 2021 May 31. Cell. 2021. PMID: 34062119 Free PMC article.
A view on drug resistance in cancer.
Vasan N, Baselga J, Hyman DM. Vasan N, et al. Nature. 2019 Nov;575(7782):299-309. doi: 10.1038/s41586-019-1730-1. Epub 2019 Nov 13. Nature. 2019. PMID: 31723286 Free PMC article. Review.
SARS-CoV-2 in immunocompromised individuals.
DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MRM, Vardhana S. DeWolf S, et al. Immunity. 2022 Oct 11;55(10):1779-1798. doi: 10.1016/j.immuni.2022.09.006. Epub 2022 Sep 13. Immunity. 2022. PMID: 36182669 Free PMC article. Review.
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT. Samstein RM, et al. Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14. Nat Genet. 2019. PMID: 30643254 Free PMC article.
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen P, Hallek M, Mey U; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Eichhorst B, et al. Ann Oncol. 2021 Jan;32(1):23-33. doi: 10.1016/j.annonc.2020.09.019. Epub 2020 Oct 19. Ann Oncol. 2021. PMID: 33091559 Free article. No abstract available.
Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis.
Mathewson ND, Ashenberg O, Tirosh I, Gritsch S, Perez EM, Marx S, Jerby-Arnon L, Chanoch-Myers R, Hara T, Richman AR, Ito Y, Pyrdol J, Friedrich M, Schumann K, Poitras MJ, Gokhale PC, Gonzalez Castro LN, Shore ME, Hebert CM, Shaw B, Cahill HL, Drummond M, Zhang W, Olawoyin O, Wakimoto H, Rozenblatt-Rosen O, Brastianos PK, Liu XS, Jones PS, Cahill DP, Frosch MP, Louis DN, Freeman GJ, Ligon KL, Marson A, Chiocca EA, Reardon DA, Regev A, Suvà ML, Wucherpfennig KW. Mathewson ND, et al. Cell. 2021 Mar 4;184(5):1281-1298.e26. doi: 10.1016/j.cell.2021.01.022. Epub 2021 Feb 15. Cell. 2021. PMID: 33592174 Free PMC article.
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Brown JR, Munir T, Mato A, Stilgenbauer S, Bajwa N, Miranda P, Higgins K, John E, de Borja M, Jurczak W, Woyach JA. Seymour JF, et al. Blood. 2023 Aug 24;142(8):687-699. doi: 10.1182/blood.2022018818. Blood. 2023. PMID: 37390310 Free PMC article. Clinical Trial.
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
Odetola O, Ma S. Odetola O, et al. Curr Hematol Malig Rep. 2023 Oct;18(5):130-143. doi: 10.1007/s11899-023-00700-z. Epub 2023 Jun 6. Curr Hematol Malig Rep. 2023. PMID: 37278884 Free PMC article. Review.
High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails.
Shy BR, Vykunta VS, Ha A, Talbot A, Roth TL, Nguyen DN, Pfeifer WG, Chen YY, Blaeschke F, Shifrut E, Vedova S, Mamedov MR, Chung JJ, Li H, Yu R, Wu D, Wolf J, Martin TG, Castro CE, Ye L, Esensten JH, Eyquem J, Marson A. Shy BR, et al. Nat Biotechnol. 2023 Apr;41(4):521-531. doi: 10.1038/s41587-022-01418-8. Epub 2022 Aug 25. Nat Biotechnol. 2023. PMID: 36008610 Free PMC article.
RASA2 ablation in T cells boosts antigen sensitivity and long-term function.
Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, Haydar D, Luetke-Eversloh M, Born-Bony M, Hegde B, Kogan S, Feuchtinger T, Okada H, Satpathy AT, Shannon K, Gottschalk S, Eyquem J, Krenciute G, Ashworth A, Marson A. Carnevale J, et al. Nature. 2022 Sep;609(7925):174-182. doi: 10.1038/s41586-022-05126-w. Epub 2022 Aug 24. Nature. 2022. PMID: 36002574 Free PMC article.
185 results